Zacks Research Predicts Bone Biologics Q1 Earnings

Bone Biologics Corp. (NASDAQ:BBLG) – Analysts at Zacks Research issued their Q1 2026 earnings estimates for shares of Bone Biologics in a research note issued on Tuesday, March 3rd. Zacks Research analyst B. Sorensen forecasts that the company will post earnings per share of ($0.54) for the quarter. The consensus estimate for Bone Biologics’ current full-year earnings is ($5.00) per share. Zacks Research also issued estimates for Bone Biologics’ Q2 2026 earnings at ($0.50) EPS, Q3 2026 earnings at ($0.46) EPS, Q4 2026 earnings at ($0.43) EPS and FY2027 earnings at ($1.62) EPS.

Separately, Weiss Ratings reiterated a “sell (e)” rating on shares of Bone Biologics in a research report on Monday, December 22nd. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has an average rating of “Sell”.

Bone Biologics Trading Up 5.7%

BBLG stock opened at $1.26 on Wednesday. The company’s 50-day moving average price is $1.48 and its 200 day moving average price is $1.87. Bone Biologics has a 52 week low of $1.11 and a 52 week high of $6.75. The company has a market cap of $2.26 million, a P/E ratio of -0.35 and a beta of 0.78.

Hedge Funds Weigh In On Bone Biologics

A hedge fund recently raised its stake in Bone Biologics stock. DRW Securities LLC raised its stake in Bone Biologics Corp. (NASDAQ:BBLG) by 113.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 23,576 shares of the company’s stock after acquiring an additional 12,549 shares during the quarter. DRW Securities LLC owned approximately 1.31% of Bone Biologics worth $34,000 at the end of the most recent quarter. 34.30% of the stock is owned by hedge funds and other institutional investors.

About Bone Biologics

Bone Biologics, Inc (NASDAQ: BBLG) is a clinical-stage biotechnology company focused on the development of cell-based therapies for skeletal repair and regeneration. The company’s research efforts center on both allogeneic and autologous mesenchymal cell platforms designed to enhance bone healing in patients with orthopedic injuries and degenerative bone conditions. Its approach aims to provide alternatives to traditional grafting procedures by harnessing the regenerative potential of specialized stem cells.

Leveraging proprietary cell expansion and delivery technologies, Bone Biologics is advancing a pipeline of investigational therapies targeting indications such as spinal fusion, long-bone non-union and maxillofacial defects.